Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Recursion Pharmaceuticals (RXRX) reported a Q4 loss of $0.53 per share, missing the Zacks Consensus Estimate of a $0.36 loss. This is a larger loss compared to $0.40 per share a year ago.
February 28, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported a larger-than-expected Q4 loss of $0.53 per share, missing the Zacks Consensus Estimate of $0.36. This indicates a worsening financial performance compared to the previous year.
The reported loss per share of $0.53 is significantly worse than the expected $0.36, indicating underperformance. This, combined with a larger loss compared to the previous year, suggests potential negative sentiment and short-term stock price pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100